Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer
Jacob E. Tallman(Vanderbilt University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center), Mia Hashibe(University of California, Los Angeles), Tatsuki Koyama(Vanderbilt University Medical Center), Sherrie H. Kaplan(University of California, Irvine), Sheldon Greenfield(University of California, Irvine), Lisa E. Paddock(Rutgers, The State University of New Jersey), Li‐Ching Huang(Vanderbilt University), Xiao‐Cheng Wu(London School of Hygiene & Tropical Medicine), Matthew R. Cooperberg(University of California, San Francisco), Christopher J.D. Wallis(University Health Network), Ann S. Hamilton(University of Southern California), Brock B. O’Neil(University of Utah), Karen E. Hoffman(The University of Texas MD Anderson Cancer Center), Antoinette M. Stroup(Rutgers, The State University of New Jersey), Zhiguo Zhao(Vanderbilt University), Michael Goodman(Emory University)
Cited by 6
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
|Nature|2008|1.3k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656